The global pharmacovigilance market, valued at USD 6.87 billion in 2023, is projected to expand at a CAGR of 13%, reaching ...

AdvaMed, the largest medical device association globally, urged the Trump administration to exempt medical products from the ...

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...

IRA has unintended consequences on investment landscape for small- and large-molecule drugs stifling the development of new ...

Nitrous oxide is widely available as long as everyone pretends it’s being used for whipped cream. An industry has arisen to ...

With pharmaceutical companies heavily investing in R&D and precision medicine, the demand for high-quality specialty APIs is ...

ACI Ltd is expanding its footprint in the pharmaceutical industry, as it announced the opening of a new subsidiary yesterday ...

Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Are you looking for high-odds, high-growth prospects to buy and hold for the next decade? That's a tall order to be sure. Most growth stocks can require a holding period of forever to realize their ...

Neither regulators nor police have attacked illegal production, promotion, and sale with sufficient vigor, perhaps because ...

AbbVie's acquisition of Allergan significantly increased the firm's debt level. We expect the firm's net debt position to peak at close to $70 billion in 2020 but given the strong cash flows of AbbVie ...